In India, weddings are not just personal milestones but large, family-led events shaped by long-held customs and expectations. In many arranged matches, appearance and financial stability still tend to influence how prospective partners are evaluated.
Against this backdrop, a new trend is emerging. Clinics are beginning to pitch weight-loss injections as part of pre-wedding grooming, with Reuters reporting a rise in inquiries from brides and even some grooms for drugs such as Mounjaro and Wegovy.
Want a ‘Mounjaro bride’?
Soon-to-be brides and grooms in India are turning to weight-loss injections as part of their wedding preparations, according to Reuters, with clinics in cities including New Delhi and Mumbai now advertising packages that combine the drugs with nutrition advice, workouts, and other makeover services.
One wellness clinic, Klarity Skin Clinic, has promoted a “Mounjaro bride” package, while other centers have folded the injections into broader “pre-wedding” transformation plans.
Doctors said inquiries have surged in recent months, with many patients specifically asking for Eli Lilly’s Mounjaro, which is the first GLP-1 medicine to enter India’s market for both diabetes and weight loss.
Also Read: Truck crushes BMW at Andhra toll plaza, High Court advocate killed in shocking highway accident
Not for cosmetic use
Several doctors said Mounjaro is now more sought after than Novo Nordisk’s Wegovy. Rajat Goel, a bariatric surgeon at Hindivine Healthcare in New Delhi, said more than 20% of the obesity-injection queries his clinic had received over the past few months were from brides-to-be. He said the drugs were prescribed only when patients were medically eligible, not for cosmetic use.
The trend comes as India’s market for anti-obesity drugs expands rapidly. Novo Nordisk and Eli Lilly introduced their obesity treatments in the country last year, with the segment projected to grow to 80 billion rupees (about $851.79 million) by 2030, according to industry estimates. Sales of Mounjaro have surged since its launch, doubling in the initial months and emerging as one of the fastest-selling therapies in India.
Access is also widening after Indian drugmakers began offering cheaper versions of Novo Nordisk’s drug following the expiry of the patent on semaglutide, its key ingredient, last month. The medicines, however, are intended for specific clinical use—typically prescribed for adults classified as obese or those who are overweight with associated conditions such as diabetes, hypertension, or sleep apnea.
